Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

REDWOOD CITY, Calif., March 17, 2026 -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026 in San Diego.

The presentations will include new Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D mutant non-small cell lung cancer, which will be featured in a plenary session.

The company will also present two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with first line metastatic pancreatic ductal adenocarcinoma (PDAC), including monotherapy data and daraxonrasib plus chemotherapy combination data, the latter of which will be featured in a mini-symposium session.

Additional presentations will highlight preclinical research supporting a new class of mutant-targeted catalytic RAS(ON) inhibitors, designed to maintain antitumor activity in the setting of emergent resistance.

Together, these presentations reflect the breadth of Revolution Medicines’ RAS(ON)-focused development strategy, spanning clinical studies across multiple tumor types and ongoing discovery efforts to address resistance and expand therapeutic opportunities for patients with RAS-driven cancers.

Details of the presentations are listed below.

Revolution Medicines Invited Presentation:

Title:	Targeting the Oncogenic State of RAS: Lessons from Tri-Complex Inhibitors
Presenter:	Mallika Singh, Ph.D., Revolution Medicines
Session:	How KRAS Inhibitors Got to the Clinic: From Discovery to Patient Benefit
Date/Time:	April 18; 3:00 p.m. – 3:20 p.m. PST

Revolution Medicines Oral Presentation:

Title:	Preliminary Safety and Clinical Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer (NSCLC)
Presenter:	Jonathan Reiss, M.D., UC Davis Comprehensive Cancer Center
Abstract Number:	CT021
Session:	New Frontiers in Precision Oncology
Date/Time:	April 19; 1:30 p.m. – 1:45 p.m. PST

Revolution Medicines Mini Symposiums:

Title:	Daraxonrasib plus Chemotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma (mPDAC)
Presenter:	Brian Wolpin, M.D., Dana-Farber Cancer Institute
Abstract Number:	LB407
Session:	Late-Breaking Research
Date/Time:	April 21; 4:05 p.m. – 4:20 p.m. PST

Title:	Discovery of a New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors with Retained Antitumor Activity in Setting of Emergent Resistance Due to Elevated RAS Flux
Presenter:	Jacqueline (Jan) Smith, Ph.D., Revolution Medicines
Abstract Number:	6782
Session:	Targeted Protein Degradation and Non-canonical Oncogenic Signaling
Date/Time:	April 21; 4:05 p.m. – 4:20 p.m. PST

Revolution Medicines Posters:

Title:	RAS(ON) Inhibition in both Cancer and Immune Cells by Daraxonrasib Drives Antitumor Immunity
Presenter:	Nataliya Shifrin, Ph.D., Revolution Medicines
Abstract Number:	2831
Session:	Immune Mechanisms Invoked by Other Therapies and Exposures
Date/Time:	April 20; 2:00 p.m. – 5:00 p.m. PST

Title:	RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-mutant NSCLC
Presenter:	Ferdinandos Skoulidis, M.D., Ph.D., MRCP, MD Anderson Cancer Center
Abstract Number:	CT215
Session:	Late-Breaking Research
Date/Time:	April 21; 9:00 a.m. – 12:00 p.m. PST

Title:	Daraxonrasib Monotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
Presenter:	Eileen O’Reilly, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number:	LB337
Session:	Late-Breaking Research: Clinical Research 3
Date/Time:	April 21; 2:00 p.m. – 5:00 p.m. PST

Title:	RAS(ON) Multi-Selective Inhibitors Stimulate the Hydrolysis of RAS-GTP to RAS-GDP and Drive Synergistic Combination Benefit with KRAS(OFF) Inhibitors in G12 Mutant Tumors
Presenter:	Kyle Seamon, Ph.D., Revolution Medicines
Abstract Number:	5696
Session:	Mechanisms of Anticancer Drug Action
Date/Time:	April 21; 2:00 p.m. – 5:00 p.m. PST

Collaborator Mini Symposium:

Title:	Active RAS Inhibition Intercepts Pancreas Cancer in Mice
Presenter:	Ben Stanger, M.D., Ph.D., Penn Pancreatic Cancer Research Center
Abstract Number:	LB406
Session:	Late-Breaking Research
Date/Time:	April 21; 3:50 p.m. – 4:05 p.m. PST

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).